Clinical trials: Pharmacotherapy
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy.
- Trial name
- NCT05635708
- Testing
- Tislelizumab, BGB-A445, LBL-007
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 418 people
- Sponsor
- BeiGene
Prostate Cancer
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with…
- Trial name
- AFFINITY (NCT01578655)
- Testing
- cabazitaxel, prednisone, custirsen sodium
- Where
- 94 sites in United States, Australia and 6 more
- Volunteers
- 630 people
- Sponsor
- Achieve Life Sciences
Head and Neck Cancer, Squamous Cell Carcinoma
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.
- Trial name
- NCT00707655
- Testing
- Zalutumumab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Genmab
Gout, Moderate Renal Impairment
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in gout participants…
- Trial name
- NCT02128490
- Testing
- Febuxostat IR, Febuxostat XR, Colchicine
- Where
- 89 sites in United States
- Volunteers
- 189 people
- Sponsor
- Takeda
Melanoma
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC).
- Trial name
- NCT00492297
- Testing
- Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
- Where
- 12 sites in France, United Kingdom
- Volunteers
- 83 people
- Sponsor
- Bayer
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Hodgkin Lymphoma
A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone
The main aim of this study conducted in Brazil is to understand if there is a difference in the length of time that Classical Hodgkin's Lymphoma (cHL) does not grow or spread further (also called progression free survival or…
- Trial name
- NCT06104878
- Testing
- No Intervention
- Where
- 6 sites in Brazil
- Sponsor
- Takeda
Small-Cell Lung Cancer
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not…
- Trial name
- NCT00466466
- Testing
- Everolimus
- Where
- 6 sites in United States, France
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose.
- Trial name
- iinnovate-3 (NCT05590377)
- Testing
- Modakafusp Alfa, Daratumumab
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Chronic Lymphocytic Leukemia
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
Primary objective: To determine overall response-rate, complete response (CR) or partial response (PR) Secondary objectives: To assess the safety and tolerability of ITF2357; to assess total rate of responders (complete + partial…
- Trial name
- NCT00792831
- Testing
- ITF2357
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Italfarmaco
Cytomegalovirus (CMV), Kidney Disease
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis).
- Conditions
- Cytomegalovirus (CMV), Kidney Disease, Kidney Failure
- Trial name
- NCT06243731
- Testing
- No Intervention
- Where
- 25 sites in Belgium, Estonia and 5 more
- Volunteers
- 10 people
- Sponsor
- Takeda
15q Duplication Syndrome, CDKL5 Deficiency Disease
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
- Trial name
- NCT03694275
- Testing
- Soticlestat
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Takeda
Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1…
- Trial name
- LATIFY (NCT05450692)
- Testing
- Ceralasertib, Durvalumab, Docetaxel
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 594 people
- Sponsor
- AstraZeneca
Breast Cancer, Neutropenia
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.
- Trial name
- NCT01648322
- Testing
- F-627, Neulasta® (pegfilgrastim)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- EVIVE Biotechnology
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
- Trial name
- NCT03341637
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Mexico
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- NCT04698681
- Where
- 63 sites in United States
- Volunteers
- 20 people
- Sponsor
- Calithera Biosciences, Inc
Neoplasms
Phase I Study in Patients With Solid Tumours
This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol.
- Trial name
- NCT00496028
- Testing
- AZD0530, Carboplatin, Paclitaxel
- Where
- 7 sites in France, Netherlands and 2 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06383767
- Testing
- ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasms, Advanced Solid
A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors
The purpose of this study is to estimate the relative bioavailability of TAK-931 tablets in reference to powder-in capsule (PIC) and to assess the effect of food and esomeprazole on the pharmacokinetics (PK) of TAK-931 as a…
- Trial name
- NCT03708211
- Testing
- TAK-931 PIC, TAK-931 Tablet, Esomeprazole
- Where
- 4 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Atherosclerotic Cardiovascular Disease
Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease
The purpose of this study is to evaluate the effect of MLN1202 on arterial inflammation in participants with stable atherosclerotic cardiovascular disease (CVD) who are receiving standard-of-care (SOC) therapy.
- Trial name
- NCT02388971
- Testing
- MLN1202
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.